Addex Therapeutics Ltd (ADXN) |
| 6.7 0.3 (4.69%) 06-04 16:00 |
| Open: | 6.7 |
| High: | 6.7 |
| Low: | 6.7 |
| Volume: | 347 |
| Market Cap: | 5(M) |
| PE Ratio: | -0.73 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 8.58 |
| Resistance 1: | 7.35 |
| Pivot price: | 6.76 |
| Support 1: | 6.50 |
| Support 2: | 5.97 |
| 52w High: | 12.05 |
| 52w Low: | 5.41 |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Financials
| EPS | -2810000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 484.343 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -4.00 |
| Return on Assets (ttm) | 882.1 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 28 May 2026
The Technical Signals Behind (ADXN) That Institutions Follow - Stock Traders Daily
Wed, 06 May 2026
Technical Reactions to ADXN Trends in Macro Strategies - Stock Traders Daily
Thu, 30 Apr 2026
Addex Therapeutics Ltd (ADXN) Q4 2025 Earnings Call Transcript Summary - Moomoo
Wed, 29 Apr 2026
Press Release: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model - Moomoo
Wed, 22 Apr 2026
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026 - Yahoo Finance
Tue, 06 Jan 2026
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
